在高血压疾病SARS-CoV-2疫苗接种队列中，妊娠期感染SARS-CoV-2未破坏子痫前期生物标志物（sFlt-1/PlGF）动态。

IF 2.9 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health Pub Date : 2025-01-31 DOI:10.1016/j.preghy.2025.101196

Guilherme Moraes Nobrega , Luciana Pietro , Sarah Luiza Dariva , Isabella Ally Vasconcelos-Silva , Monique Possari Manari , Barbara Polli , Arthur Becker Simões , Julia Stucker de Almeida , Roberta Moschetta , Carolina Carvalho Ribeiro-do-Valle , Jose Paulo Siqueira Guida , Renato Teixeira Souza , Jose Guilherme Cecatti , Indira U Mysorekar , Ana Selma Picoloto , Maria Laura Costa

{"title":"在高血压疾病SARS-CoV-2疫苗接种队列中，妊娠期感染SARS-CoV-2未破坏子痫前期生物标志物（sFlt-1/PlGF）动态。","authors":"Guilherme Moraes Nobrega , Luciana Pietro , Sarah Luiza Dariva , Isabella Ally Vasconcelos-Silva , Monique Possari Manari , Barbara Polli , Arthur Becker Simões , Julia Stucker de Almeida , Roberta Moschetta , Carolina Carvalho Ribeiro-do-Valle , Jose Paulo Siqueira Guida , Renato Teixeira Souza , Jose Guilherme Cecatti , Indira U Mysorekar , Ana Selma Picoloto , Maria Laura Costa","doi":"10.1016/j.preghy.2025.101196","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To analyze maternal and perinatal outcomes and serum levels of the preeclampsia (PE) biomarkers sFlt-1 and PlGF in pregnant women with hypertensive disorders vaccinated against SARS-CoV-2, with or without confirmed COVID-19 during pregnancy.</div></div><div><h3>Methods</h3><div>Multicenter (two-center) prospective cohort study secondary analysis. The cohort comprised pregnant women with hypertensive disorders who received SARS-CoV-2 vaccination, assessed from August 2021 to December 2022. Key variables included sociodemographic information, clinical background, maternal and perinatal outcomes, and biomarkers serum concentrations. A sFlt-1/PlGF ratio ≥ 38 was the threshold for predicting PE. The study compared outcomes based on the timing of SARS-CoV-2 infection and PE clinical onset.</div></div><div><h3>Results</h3><div>For biomarker analysis, 170 women provided serum samples: 31 had a confirmed COVID-19 during pregnancy, while 139 did not. Among these 170 women, 86 had chronic hypertension, and 100 developed PE. There were no significant differences in sociodemographic characteristics and gestational outcomes between the groups. The dynamics of the sFlt-1/PlGF ratio were similar regardless of COVID-19. Cesarean delivery was the most common delivery method in both groups, and there was a high rate of preterm births. No neonatal or maternal deaths were recorded.</div></div><div><h3>Conclusions</h3><div>The study suggests that pregnant women with hypertensive disorders who have been vaccinated against SARS-CoV-2 and subsequently infected show comparable maternal and perinatal outcomes and PE biomarker levels to those who were not infected. These results suggest that SARS-CoV-2 vaccination is protective for pregnant women, potentially reducing the association with a <em>PE-like</em> syndrome in severe cases of COVID-19 among those who are unvaccinated.</div></div>","PeriodicalId":48697,"journal":{"name":"Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health","volume":"39 ","pages":"Article 101196"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preeclampsia biomarkers (sFlt-1/PlGF) dynamics are not disrupted by SARS-CoV-2 infection during pregnancy in a hypertensive disorder SARS-CoV-2 vaccinated cohort\",\"authors\":\"Guilherme Moraes Nobrega , Luciana Pietro , Sarah Luiza Dariva , Isabella Ally Vasconcelos-Silva , Monique Possari Manari , Barbara Polli , Arthur Becker Simões , Julia Stucker de Almeida , Roberta Moschetta , Carolina Carvalho Ribeiro-do-Valle , Jose Paulo Siqueira Guida , Renato Teixeira Souza , Jose Guilherme Cecatti , Indira U Mysorekar , Ana Selma Picoloto , Maria Laura Costa\",\"doi\":\"10.1016/j.preghy.2025.101196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>To analyze maternal and perinatal outcomes and serum levels of the preeclampsia (PE) biomarkers sFlt-1 and PlGF in pregnant women with hypertensive disorders vaccinated against SARS-CoV-2, with or without confirmed COVID-19 during pregnancy.</div></div><div><h3>Methods</h3><div>Multicenter (two-center) prospective cohort study secondary analysis. The cohort comprised pregnant women with hypertensive disorders who received SARS-CoV-2 vaccination, assessed from August 2021 to December 2022. Key variables included sociodemographic information, clinical background, maternal and perinatal outcomes, and biomarkers serum concentrations. A sFlt-1/PlGF ratio ≥ 38 was the threshold for predicting PE. The study compared outcomes based on the timing of SARS-CoV-2 infection and PE clinical onset.</div></div><div><h3>Results</h3><div>For biomarker analysis, 170 women provided serum samples: 31 had a confirmed COVID-19 during pregnancy, while 139 did not. Among these 170 women, 86 had chronic hypertension, and 100 developed PE. There were no significant differences in sociodemographic characteristics and gestational outcomes between the groups. The dynamics of the sFlt-1/PlGF ratio were similar regardless of COVID-19. Cesarean delivery was the most common delivery method in both groups, and there was a high rate of preterm births. No neonatal or maternal deaths were recorded.</div></div><div><h3>Conclusions</h3><div>The study suggests that pregnant women with hypertensive disorders who have been vaccinated against SARS-CoV-2 and subsequently infected show comparable maternal and perinatal outcomes and PE biomarker levels to those who were not infected. These results suggest that SARS-CoV-2 vaccination is protective for pregnant women, potentially reducing the association with a <em>PE-like</em> syndrome in severe cases of COVID-19 among those who are unvaccinated.</div></div>\",\"PeriodicalId\":48697,\"journal\":{\"name\":\"Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health\",\"volume\":\"39 \",\"pages\":\"Article 101196\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2210778925000121\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210778925000121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：分析妊娠期已确诊或未确诊COVID-19的高血压疾病孕妇接种SARS-CoV-2疫苗后的孕产妇和围产期结局及子痫前期（PE）生物标志物sFlt-1和PlGF的血清水平。方法：多中心（双中心）前瞻性队列研究，二次分析。该队列包括在2021年8月至2022年12月期间接受SARS-CoV-2疫苗接种的高血压疾病孕妇。关键变量包括社会人口统计信息、临床背景、孕产妇和围产期结局以及生物标志物血清浓度。sFlt-1/PlGF比值≥38是预测PE的阈值。该研究比较了基于SARS-CoV-2感染时间和PE临床发病的结果。结果：在生物标志物分析中，170名妇女提供了血清样本：31名妇女在怀孕期间确诊了COVID-19, 139名妇女没有。在这170名女性中，86名患有慢性高血压，100名患有PE。两组之间的社会人口学特征和妊娠结局无显著差异。sFlt-1/PlGF比值的动态与COVID-19无关。剖宫产是两组中最常见的分娩方式，早产率较高。没有新生儿或产妇死亡记录。结论：该研究表明，接种过SARS-CoV-2疫苗并随后感染的高血压疾病孕妇的孕产妇和围产期结局以及PE生物标志物水平与未感染的孕妇相当。这些结果表明，接种SARS-CoV-2疫苗对孕妇有保护作用，可能会降低未接种疫苗的严重COVID-19病例与pe样综合征的关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Preeclampsia biomarkers (sFlt-1/PlGF) dynamics are not disrupted by SARS-CoV-2 infection during pregnancy in a hypertensive disorder SARS-CoV-2 vaccinated cohort

Objectives

To analyze maternal and perinatal outcomes and serum levels of the preeclampsia (PE) biomarkers sFlt-1 and PlGF in pregnant women with hypertensive disorders vaccinated against SARS-CoV-2, with or without confirmed COVID-19 during pregnancy.

Methods

Multicenter (two-center) prospective cohort study secondary analysis. The cohort comprised pregnant women with hypertensive disorders who received SARS-CoV-2 vaccination, assessed from August 2021 to December 2022. Key variables included sociodemographic information, clinical background, maternal and perinatal outcomes, and biomarkers serum concentrations. A sFlt-1/PlGF ratio ≥ 38 was the threshold for predicting PE. The study compared outcomes based on the timing of SARS-CoV-2 infection and PE clinical onset.

Results

For biomarker analysis, 170 women provided serum samples: 31 had a confirmed COVID-19 during pregnancy, while 139 did not. Among these 170 women, 86 had chronic hypertension, and 100 developed PE. There were no significant differences in sociodemographic characteristics and gestational outcomes between the groups. The dynamics of the sFlt-1/PlGF ratio were similar regardless of COVID-19. Cesarean delivery was the most common delivery method in both groups, and there was a high rate of preterm births. No neonatal or maternal deaths were recorded.

Conclusions

The study suggests that pregnant women with hypertensive disorders who have been vaccinated against SARS-CoV-2 and subsequently infected show comparable maternal and perinatal outcomes and PE biomarker levels to those who were not infected. These results suggest that SARS-CoV-2 vaccination is protective for pregnant women, potentially reducing the association with a PE-like syndrome in severe cases of COVID-19 among those who are unvaccinated.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health OBSTETRICS & GYNECOLOGYPERIPHERAL VASCULAR-PERIPHERAL VASCULAR DISEASE

CiteScore

4.90

自引率

0.00%

发文量

127

期刊介绍： Pregnancy Hypertension: An International Journal of Women''s Cardiovascular Health aims to stimulate research in the field of hypertension in pregnancy, disseminate the useful results of such research, and advance education in the field. We publish articles pertaining to human and animal blood pressure during gestation, hypertension during gestation including physiology of circulatory control, pathophysiology, methodology, therapy or any other material relevant to the relationship between elevated blood pressure and pregnancy. The subtitle reflects the wider aspects of studying hypertension in pregnancy thus we also publish articles on in utero programming, nutrition, long term effects of hypertension in pregnancy on cardiovascular health and other research that helps our understanding of the etiology or consequences of hypertension in pregnancy. Case reports are not published unless of exceptional/outstanding importance to the field.